Literature DB >> 20670161

New promising Euphorbiaceae extracts with activity in human lymphocytes from primary cell cultures.

Doris S Llanes-Coronel1, Laura Y Gámez-Díaz, Leidy P Suarez-Quintero, Lady J Páez, Fernando Torres, Fernando Echeverri, Alicia Ponte-Sucre, Pablo J Patiño, Claudia M Trujillo-Vargas.   

Abstract

CONTEXT: Euphorbiaceae plants exhibit anti-inflammatory and immunomodulatory properties.
METHODS: We evaluated the activity of 14 extracts from seven Euphorbiaceae plants on primary immune cell cultures from healthy individuals. Peripheral blood mononuclear cells (PBMC) were exposed to the extracts w/o phytohaemagglutinin A or cycloheximide as agents that induce proliferation or apoptosis in PBMC, respectively.
RESULTS: We found that five up to 14 Euphorbiaceae's extracts had the ability to modulate at least one of the immune parameters evaluated in this study. However, only the latex extracts of Euphorbia cotinifolia and Euphorbia tirucalli strongly induced both proliferation and apoptosis in PBMC. These extracts were further subfractioned by silica gel column chromatography. Two subfractions with enhanced activity in comparison to the crude extracts were obtained. Although these subfractions induced proliferation on both CD3(+) and CD3(-) cells, the most prominent effects were observed in the former subpopulation. Interestingly, the subfraction from E. tirucalli induced lymphocyte proliferation without the need of accessory cells; this ability was not inhibited by the carbohydrates d-galactose and α-Methyl-D-Mannopyranoside.
CONCLUSIONS: Altogether, these results reveal the presence of novel candidates within the Euphorbia plants to induce proliferation and apoptosis in human lymphocytes, mainly in CD3(+) T cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20670161     DOI: 10.3109/08923973.2010.502173

Source DB:  PubMed          Journal:  Immunopharmacol Immunotoxicol        ISSN: 0892-3973            Impact factor:   2.730


  6 in total

1.  Anti-inflammatory activity of Euphorbia aegyptiaca extract in rats.

Authors:  Marium A Abo-Dola; Mohamed F Lutfi
Journal:  Int J Health Sci (Qassim)       Date:  2016-01

2.  Attenuation of nociceptive pain and inflammatory disorders by total steroid and terpenoid fraction of Euphorbia tirucalli Linn root in experimental in vitro and in vivo model.

Authors:  Partha Palit; Dhrubojyoti Mukherjee; Poulami Mahanta; Md Shadab; Nahid Ali; Shubhadeep Roychoudhury; Md Asad; Subhash C Mandal
Journal:  Inflammopharmacology       Date:  2017-10-23       Impact factor: 4.473

3.  EFFECTS OF TOPICAL TREATMENT WITH EUPHORBIA TIRUCALLI LATEX ON THE SURVIVAL AND INTESTINAL ADHESIONS IN RATS WITH EXPERIMENTAL PERITONITIS.

Authors:  Lilhian Alves de Araújo; Fátima Mrué; Roberpaulo Anacleto Neves; Maxley Martins Alves; Nelson Jorge da Silva-Júnior; Marcelo Seixo de Brito Silva; Paulo Roberto de Melo-Reis
Journal:  Arq Bras Cir Dig       Date:  2015 Nov-Dec

4.  Antioxidant and Antiproliferative Activities of Leaf Extracts from Plukenetia volubilis Linneo (Euphorbiaceae).

Authors:  Ana Karina Lima Nascimento; Raniere Fagundes Melo-Silveira; Nednaldo Dantas-Santos; Júlia Morais Fernandes; Silvana Maria Zucolotto; Hugo Alexandre Oliveira Rocha; Katia Castanho Scortecci
Journal:  Evid Based Complement Alternat Med       Date:  2013-09-18       Impact factor: 2.629

5.  EBV Reactivation and Chromosomal Polysomies: Euphorbia tirucalli as a Possible Cofactor in Endemic Burkitt Lymphoma.

Authors:  Susanna Mannucci; Anna Luzzi; Alessandro Carugi; Alessandro Gozzetti; Stefano Lazzi; Valeria Malagnino; Monique Simmonds; Maria Grazia Cusi; Lorenzo Leoncini; Cornelia A van den Bosch; Giulia De Falco
Journal:  Adv Hematol       Date:  2012-04-24

Review 6.  Medicinal Plants from Mexico, Central America, and the Caribbean Used as Immunostimulants.

Authors:  Angel Josabad Alonso-Castro; María Del Carmen Juárez-Vázquez; Nimsi Campos-Xolalpa
Journal:  Evid Based Complement Alternat Med       Date:  2016-03-03       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.